Idenix Pharmaceuticals has entered a license agreement granting GlaxoSmithKline (GSK) exclusive worldwide rights to IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development for the treatment of HIV/AIDS. To date, IDX899 has demonstrated high potency with low doses, a high barrier to drug resistance, favorable risk/benefit profile, and the convenience of once-a-day administration. GSK will assume responsibility for the development and costs associated w...